Roche's core earnings for 2025 reached CHF 15.62 billion, representing 4% year-on-year growth from CHF 18.80 per share to CHF 19.46 per share[2]. The company originally planned for high single-digit underlying profit growth in 2025, to follow strong results in 2024 thanks to strong sales in both the drugs and diagnostics divisions[1]. Earnings were largely in line with analysts' expectations. The company's net profit increased by 50% to CHF 13.8 billion from CHF 9.19 billion in the previous year[6]. The weakening of the US dollar had a negative impact on the company's profits, as the US represents a key market where Roche realized almost 48% of total sales in 2024[3]. The US dollar weakened against the euro by more than 12% from January to mid-June 2025[8]. Despite the exchange rate challenges, Roche maintained a positive outlook and continued to diversify its product portfolio.